OpenNeedle Ask your own

Question explored with the scientific record

What about monoclonal antibody infusion for Covid 19 and 7 months pregnant

Nov 16, 2026 · 2 sources used · OpenNeedle synthesis
The short version: the evidence on monoclonal antibodies in pregnancy is a handful of case reports, and none of it tells you what monitoring to do afterward.

The best record is seven unvaccinated pregnant women hospitalized with COVID who got casirivimab and imdevimab; all had favorable outcomes and no drug reactions, but six of seven were at or near term, not seven months [1]. A second series of 21 pregnant patients found mostly favorable short-term outcomes but one anaphylaxis, one intensive-care admission, and a high rate of pregnancy complications among those who delivered [2]. Both are uncontrolled case series. Nobody was compared to untreated pregnant women, so the drug's benefit is asserted, not proven.

FindingCount
Pregnant patients treated (series 2)21
Anaphylaxis1
Intermediate-care admission1
Adverse pregnancy outcomes among delivered43.7% of 16

For monitoring after the infusion, no record here gives a schedule. General practice, outside these records, is to watch for an allergic reaction during and shortly after the infusion, then watch the pregnancy itself: fetal movement, growth, and blood pressure. At seven months the fetus is the thing to track, not the drug level.

My call: the benefit for a seven-month pregnant woman is unproven and the safety data is a few dozen cases at most, so this is a decision to make with the actual risk of her COVID weighed honestly, not a routine. Confidence: low.

Keep digging

Sources used 2

  1. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy Infection (2022) Thin

    This study reports the clinical outcomes of seven unvaccinated pregnant women hospitalized with COVID-19 who were treated with monoclonal antibodies casirivimab and imdevimab, highlighting favorable outcomes with no adverse drug reactions.

    DOI: 10.1007/s15010-022-01829-4
  2. Short-Term Pregnancy Outcomes Following Monoclonal Antibody Treatment for COVID-19 Infection during the Omicron Surge Women's Health Science Journal (2022) Thin

    A small retrospective case series describing short-term outcomes of monoclonal antibody therapy for COVID-19 in 21 pregnant patients during the Omicron surge, noting generally favorable maternal outcomes but notable obstetric complications and a few adverse events.

    DOI: 10.23880/whsj-16000167

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →